ASCO Annual Meeting

Multiple Myeloma Progression Still Slowed With Reduced Tecvayli Dosing

June 17th 2024, 3:00pm

Article

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

Don’t Delay Bringing Up CML Concerns, a Doctor Says

June 15th 2024, 2:00pm

Video

To ensure best outcomes, patients with chronic myeloid leukemia should maintain frequent communication with their care teams — even between appointments.

Most Patients With CML Can Continue Their Normal Lifestyle During Treatment

June 14th 2024, 10:00pm

Video

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said.

Organizations Can Help Patients with CML Face the ‘Long Treatment Journey’

June 14th 2024, 9:00pm

Video

A chronic myeloid leukemia diagnosis can negatively affect patients and their loved ones’ mental health, but there are resources that can help.

Putting Quality of Life into Perspective During CML Treatment

June 13th 2024, 9:00pm

Video

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

Understanding the Disease, Treatments Help Patients Navigate a CML Diagnosis

June 13th 2024, 1:00pm

Video

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis.

3 Questions to Ask Doctors After a CML Diagnosis

June 12th 2024, 8:00pm

Video

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia.

Tumor Treating Fields for Brain Metastases in Lung Cancer Boost Quality of Life With Some Trade-Offs

June 11th 2024, 9:00pm

Video

For patients with non-small lung cancer and brain metastases, it’s important to consent to shaving the scalp before tumor-treating fields therapy.

Tecvayli Responses Continue for Two Years in R/R Multiple Myeloma

June 10th 2024, 9:00pm

Article

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

4-Drug Regimen Boosts Time to Progression in Newly Diagnosed Myeloma

June 8th 2024, 2:00pm

Article

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.